Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Tumor Vaccination Success: Vaccination with tumor-specific antigens is one of several attempted therapies seeking to harness the immune system, but—unfortunately—this strategy has been unsuccessful, possibly because of the immunosuppressive properties of the tumor microenvironment. Kraman et al. (p. 827 ; see the Perspective by Schreiber and Rowley ) have identified immunosuppressive cells of mesenchymal origin in mice comprising 2% of the tumor stromal cell population. They were identified by expression of the fibroblast activation protein–α. Deletion of these cells in lung or pancreatic cancers in mice allowed successful therapeutic vaccination against the tumors, which was dependent on the adaptive immune system and the cytokines interferon-γ and tumor necrosis factor–α. These findings reveal that multiple cell types contribute to the immunosuppressive tumor microenvironment and will inform therapeutic cancer vaccine design.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In view of the critical role of CAFs in the design of TME, the therapeutic options for deactivating CAF-mediated interaction are largely focused on using/reprogramming or eliminating of CAFs [76–78].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [76]
In the citing paper
“coordinate the function of the immune system via the production of chemokines and cytokines, although it should be noted that there is heterogeneity in the cytokines produced by different fibroblasts16–20.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“However, the situation with tumour necrosis factor (TNF) produced by CAFs is more nuanced; the tumour-promoting immunosuppressive activity of FAP+ fibroblasts is associated with suppression of TNF signalling, yet TNF is also able to drive fibroblast activation in certain contexts16,124,125.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004) · Blood · doi:10.1182/blood-2003-09-3070 · Cited by 994
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Cited by
Items 801–900 of 1,000
Zhou, Q., Jin, X., Zhao, Y., Wang, Y., Tao, M., Cao, Y., & Yin, X. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae056 · Cited by 16
“The increased expression of FAP in CAFs exhibits an inverse correlation with patient survival, and the depletion of these FAP( + ) CAFs leads to reduced murine tumor outgrowth [59].”
BackgroundRodriguez, B. L., Huang, J., Gibson, L., Fradette, J. J., Chen, H.-I. H., Koyano, K., Cortez, C. A., Li, B., Ho, C., Ashique, A. M., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0866 · Cited by 15
Corvigno, S., Fernebro, J., Karlsson, J. S., Mezheieusky, A., Martín-Bernabé, A., de la Fuente, L. M., Westbom-Fremer, S., Carlson, J. W., Klein, C., Kannisto, P., et al. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.01.010 · Cited by 16
Cancer-associated fibroblasts: Just on the opposite side of antitumour immunity?
Guo, S., Yuan, J., Meng, X., Feng, X., Ma, D., Han, Y., & Li, K. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110601 · Cited by 17
Modulation of Tumor Tolerance in Primary Central Nervous System Malignancies
Johnson, T. S., Munn, D. H., & Maria, B. L. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/937253 · Cited by 15
Duncan, B. B., Highfill, S. L., Qin, H., Bouchkouj, N., Larabee, S. M., Zhao, P., Woźnica, I., Liu, Y., Li, Y., Wu, W., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182a80213 · Cited by 17
Malchiodi, Z. X., Cao, H., Gay, M. D., Safronenka, A., Bansal, S., Tucker, R. D., Weinberg, B. A., Cheema, A. K., Shivapurkar, N., & Smith, J. P. (2021) · Cancers · doi:10.3390/cancers13194949 · Cited by 15
Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases
Osborne, N., Sundseth, R., Gay, M. D., Cao, H., Tucker, R. D., Nadella, S., Wang, S., Liu, X., Kroemer, A., Sutton, L. Y., et al. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00145.2019 · Cited by 15
Turan, T., Kongpachith, S., Halliwill, K. D., Roelands, J. P., Hendrickx, W., Marincola, F. M., Hudson, T. J., Jacob, H. J., Bedognetti, D., Samayoa, J. A., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01193-w · Cited by 15
Wu, Y., Wei, B., Wei, Z., Wang, H., Liu, Y., Xu, D., Li, X., Guo, L., Lu, H., & Shang, H. (2025) · Communications Biology · doi:10.1038/s42003-025-09310-2 · Cited by 14
Challenges in the preclinical design and assessment of CAR-T cells
Tomai, R. A., Rivas, J. D. L., Fetică, B., Bergantim, R., Filipić, B., Gagić, Ž., Nikolic, K. M., Gulei, D., Kegyes, D., Nistor, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1564998 · Cited by 15
Zhang, Y., & Liu, Z. (2025) · Advanced Science · doi:10.1002/advs.202508692 · Cited by 18
Interventions that induce modifications in the tumor microenvironment
Bernhard, E. J. (2011) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2011.01.007 · Cited by 16
“Activation of tumornfiltrating T-cells and the resulting increase in interferon- and NF- promoted the anti-tumor immune response in a transenic mouse model [100].”
BackgroundEltoukhy, H. S., Sinha, G., Moore, C. A., Sandiford, O. A., & Rameshwar, P. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.07.011 · Cited by 14
Fibroblast activation protein (FAP) as a possible target of the antitumor strategy
Pleshkan, V. V., Алексеенко, И. В., Tyulkina, D. V., Kyzmich, A. I., Zinovyeva, M. V., & Sverdlov, E. D. (2016) · Molecular Genetics Microbiology and Virology (Russian) · doi:10.18821/0208-0613-2016-34-3-90-97 · Cited by 14
Yang, X., Lu, Y., Xu, J., Du, Y., & Yu, R. (2023) · Molecules · doi:10.3390/molecules28031506 · Cited by 14
“It is not only related to the progression and metastasis of PDAC, but also affects the immune microenvironment and cell metabolism [93,94].”
BackgroundSmeets, E., Dorst, D. N., Franssen, G. M., ESSEN, M. V., Frielink, C., Stommel, M. W. J., Trajkovic‐Arsic, M., Cheung, P. F., Siveke, J. T., Wilson, I., et al. (2023) · Cells · doi:10.3390/cells12101420 · Cited by 14
“Depletion of FAP-expressing cells was investigated in transgenic mice with FAP-promotor driven diphtheria toxin receptor (DTR) [5] or using pharmacological FAP inhibitors [8], FAP-targeting vaccines and T-cell therapies [9–12], and FAP-targeting molecules coupled to cytotoxic compounds [13–17].”
BackgroundAlonso-Moreda, N., Berral-González, A., Rosa, E. D. L., González-Velasco, Ó., Sánchez-Santos, J. M., & Rivas, J. D. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310765 · Cited by 16
Fibroblast-activation protein: valuable marker of cutaneous epithelial malignancy
Khoury, J. R. E., Kurban, M., Kibbi, A., & Abbas, O. M. (2014) · Archives of Dermatological Research · doi:10.1007/s00403-014-1456-8 · Cited by 14
“Another mechanism by which FAP promotes tumor growth is through the suppression of antitumor immunity [26].”
BackgroundWalentowicz‐Sadlecka, M., Koper, A., Gałązka, K., Koper, K., Basta, P., Mach, P., Skręt-Magierło, J. E., Dutsch‐Wicherek, M., Sikora, J., Grabiec, M., et al. (2013) · American Journal of Reproductive Immunology · doi:10.1111/aji.12120 · Cited by 15
Hickman, O. J., Smith, R. A., Prokar Dasgupta, A., Rao, S. N., Nayak, S., Sreenivasan, S., Vyakarnam, A., & Galustian, C. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.91 · Cited by 14
“Indeed, elimination of certain stromal compartments is sufficient to induce complete regression of tumours in mice, highlighting the significance of a dysfunctional stroma in tumour growth and survival (Kraman et al, 2010).”
BackgroundLee, J. H., Kim, H. M., & Koo, J. S. (2018) · Pathobiology · doi:10.1159/000492392 · Cited by 14
Wei, X., Wu, J., Cao, W., Chen, Q., Shao, Z., Hu, C., Zhang, Y., Weng, W., Meng, T., Meng, X., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03567-x · Cited by 14
Kong, B., Fan, Q., Wang, X., Zhang, Q. H., & Zhang, G. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i26.3101 · Cited by 13
Gu, L., Ding, D., Wei, C., & Zhou, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1158863 · Cited by 14
“As a key component of the tumor matrix, cancer-associated fibroblasts (CAFs) secrete several growth factors and cytokines, which are important for promoting tumor progression and migration (13, 14), stimulating epithelial-mesenchymal transition (EMT) (15, 16) and inducing chemical resistance (17, 18) and immunosuppres…”
BackgroundArming Vδ2 T Cells with Chimeric Antigen Receptors to Combat Cancer
Thomas, P., Paris, P., & Pecqueur, C. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3495 · Cited by 13
Carlomagno, S., Setti, C., Ortolani, F., & Sivori, S. (2024) · Immunology Letters · doi:10.1016/j.imlet.2024.106898 · Cited by 13
Arauchi, A., Yang, C.-H., Cho, S., Jarboe, E. A., Peterson, C. M., Bae, Y. H., Okano, T., & Janat-Amsbury, M. M. (2014) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2014.0040 · Cited by 13
Multifaceted Tumor Stromal Fibroblasts
Li, J., Chen, L., & Qin, Z. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0109-8 · Cited by 16
Flow Cytometric Identification of Fibrocytes in the Human Circulation
Hu, X., DeBiasi, E. M., & Herzog, E. L. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2963-4_3 · Cited by 13
Targeting STAT3 Signaling in COL1+ Fibroblasts Controls Colitis-Associated Cancer in Mice
Heichler, C., Schmied, A., Enderle, K., Koop, K., Murawska, M., Schmid, B., Waldner, M. J., Neurath, M. F., & Neufert, C. F. (2022) · Cancers · doi:10.3390/cancers14061472 · Cited by 13
Selection and Identification of an ssDNA Aptamer for Fibroblast Activation Protein
Zhang, X., Yang, G. H., Zhao, Y., Dai, X., Liu, W., Qu, F., & Huang, Y. (2023) · Molecules · doi:10.3390/molecules28041682 · Cited by 13
Dong, L., Sun, Q., Song, F., Song, X., Lu, C., Li, Y., & Song, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14003 · Cited by 13
Keane, F. M., Chowdhury, S., Yao, T.-W., Nadvi, N. A., Gall, M. G., Chen, Y., Osborne, B., de Ribeiro, A. J. V., Church, W. B., McCaughan, G. W., et al. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/9781849733151-00118 · Cited by 13
Shao, H., Moller, M. G., Cai, L., Prokupets, R., Yang, C., Costa, C., Yu, K., Le, N., & Liu, Z. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248260 · Cited by 14
“Additionally, CAFs play a part in drug resistance and tumor recurrence [5, 6].”
BackgroundFibroblast activation protein is dispensable in the anti-influenza immune response in mice
Tan, S., Chowdhury, S., Polak, N., Gorrell, M. D., & Weninger, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171194 · Cited by 14
Ariyoshi, M., Yuge, R., Kitadai, Y., Shimizu, D., Miyamoto, R., Yamashita, K., Hiyama, Y., Takigawa, H., Urabe, Y., & Oka, S. (2024) · Cancers · doi:10.3390/cancers16183136 · Cited by 12
“Stromal components have been reported to act as barriers to immune cell infiltration in various carcinomas [36–38].”
BackgroundThe Role and Application of Fibroblast Activating Protein
Zhang, X.-L., Wang, X., Qian, J., Yang, W.-J., Xu, H., Xu, X.-D., & Zhang, G. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230530095305 · Cited by 12
The reactive stroma response regulates the immune landscape in prostate cancer
Thomas, R., Jerome, J. M., Krieger, K. L., Ashraf, N., & Rowley, D. R. (2024) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2024.15 · Cited by 14
Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
Dimitrieva, S., Harrison, J. M., Chang, J. E., Piquet, M., Mino-Kenudson, M. A., Gabriel, M., Sagar, V., Horn, H., Lage, K., Kim, J., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0489 · Cited by 12
Prado‐Lòpez, S., Duffy, M. M., Baustian, C., Alagesan, S., Hanley, S. A., Stocca, A., Griffin, M. D., & Ceredig, R. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.30 · Cited by 14
Management of Metastatic Pancreatic Adenocarcinoma
Cheema, A. R., & O'Reilly, E. M. (2016) · Surgical Clinics of North America · doi:10.1016/j.suc.2016.07.011 · Cited by 12
Sliker, B. H., & Campbell, P. M. (2021) · Vaccines · doi:10.3390/vaccines9060634 · Cited by 13
Molecular targets and therapeutic strategies for triple-negative breast cancer
Bhat, Y., Thrishna, M. R., & Banerjee, S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08868-6 · Cited by 12
Lubuela, G., Bèaufrere, A., Albuquerque, M., Pignollet, C., Nicolle, R., Lesurtel, M., Bouattour, M., Cros, J. F., & Paradis, V. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03922-5 · Cited by 12
“Indeed, according to a few studies [11, 27, 28], tumour FAP expression has been found associated with a shift in immune cell populations promoting immunosuppression.”
Görgün, G., & Anderson, K. C. (2011) · Immunotherapy · doi:10.2217/imt.11.124 · Cited by 12
In Vitro and Ex Vivo Models – The Tumor Microenvironment in a Flask
Pinto, C., Estrada, M. F., & Brito, C. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34025-4_23 · Cited by 12
Biophysics involved in the process of tumor immune escape
Wang, M., Jiang, H., Liu, X., & Wang, X. (2022) · iScience · doi:10.1016/j.isci.2022.104124 · Cited by 16
“The unstructured C-terminal tail was found to be important for the function of immune proteins (Kristiansen et al., 2016).”
BackgroundFibroblast activation protein (FAP) as a possible target of an antitumor strategy
Pleshkan, V. V., Алексеенко, И. В., Tyulkina, D. V., Kyzmich, A. I., Zinovyeva, M. V., & Sverdlov, E. D. (2016) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416816030083 · Cited by 12
Fibroblast Activation Protein α
Gorrell, M. D., & Park, J. E. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382219-2.00750-x · Cited by 12
Li, X., Huang, F., Xu, X., & Hu, S. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.26520 · Cited by 11
Eskandari-Malayeri, F., Rezeai, M., Narimani, T., Esmaeil, N., & Azizi, M. (2024) · Discover Oncology · doi:10.1007/s12672-024-01156-0 · Cited by 12
“Depletion of the FAP-positive fibroblast population in transgenic mice led to cytokine-mediated hypoxic necrosis of both the tumor and the stroma [28].”
BackgroundZhang, J., Huang, J., Yang, Q., Zeng, L., & Deng, K. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150915 · Cited by 11
Li, Y., He, C., Shen, A. N., Wang, Y., Xu, Z. P., Zhang, L. L., & Wang, R. (2025) · ACS Omega · doi:10.1021/acsomega.4c09716 · Cited by 11
Benign non-immune cells in tumor microenvironment
Liu, S., Liu, C., He, Y., & Li, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561577 · Cited by 11
Li, Y., Tang, Y., Chen, S., Liu, Y., Wang, S., Tian, Y., Wang, C., Teng, Z., & Lu, G. (2019) · RSC Advances · doi:10.1039/c9ra02180a · Cited by 11
A cell-based fluorescent assay for FAP inhibitor discovery
Zhang, B., Liu, F., Yang, M.-F., Xu, J., Wang, Z., Zhang, J., Wang, R., & Yang, X. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127253 · Cited by 12
Stromal Cell Induction of Regulatory Dendritic Cells
Owens, B. M. J., & Kaye, P. M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00262 · Cited by 11
“…2011), specific enzymatic degradation of tumor stroma to enhance stromal remodeling (Provenzano et al., 2012), and therapeutic ablation of cancer stromal cells in murine tumor models (Kraman et al., 2010), but stromal targeting approaches are not usually considered in other therapeutic contexts.”
BackgroundAntitumor immunity targeting fibroblast activation protein‑α in a mouse Lewis lung carcinoma model
Xie, J., Yuan, S., Peng, L., Li, H., Niu, L., Xu, H. M., Guo, X., Yang, M., & Duan, F.-Y. (2020) · Oncology Letters · doi:10.3892/ol.2020.11637 · Cited by 12
Breast Cancer Stem Cells Upregulate IRF6 in Stromal Fibroblasts to Induce Stromagenesis
Muralidharan, H., Hansen, T. V. O., Steinle, A., Schumacher, D., Stickeler, E., & Maurer, J. (2024) · Cells · doi:10.3390/cells13171466 · Cited by 10
“…from our experiments also link the IRF6 expression in activated stromal fibroblasts to BCSC cell survival and a reduction in necrosis, which is similar to a previous study that observed the depletion of FAP + CAFs in the TME to be associated with necrosis in Lewis lung carcinoma mouse models [80].”
ResultInterrogation of the tumor microenvironment by nanoparticles
Panja, P., Manne, U., Awasthi, V., Bhattacharya, R., & Mukherjee, P. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217454 · Cited by 10
Fibroblast Activation Protein-Targeted Theranostics: Current Status in Clinical Development
Kang, Y.-K. (2025) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-025-00935-z · Cited by 10
“…extracellular matrix remodeling, thereby facilitating tumor invasion and progression [3, 6 ], but it also participates in establishing an immunosuppressive tumor microenvironment by modulating various immune cells including macrophages, natural killer cells, or regula - tory T cells [7, 8 ].”
The tumor ecosystem: Rewiring an open, systemically integrated network for therapeutic gain
Chiodelli, P., Papait, A., Agoni, L., Quaglia, F., Silini, A. R., & Parolini, O. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119047 · Cited by 12
Carter, J. A., Dickerson, L. K., Stephanou, A., Damle, S., Goodsell, K. E., Daniel, S. K., Sullivan, K. M., Shui, B., Jiang, X., Kenerson, H. L., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2025.10.006 · Cited by 10
Koeck, S., Zwierzina, M., Huber, J., Bitsche, M., Lorenz, E., Gamerith, G., Dudás, J., Kelm, J. M., Zwierzina, H., & Amann, A. (2016) · Immunobiology · doi:10.1016/j.imbio.2015.12.010 · Cited by 11
Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles
Kumar, V., & Mahato, R. I. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216462 · Cited by 12
Feng, J., Goedegebuure, S. P., Zeng, A., Bi, Y., Wang, T., Payne, P., Ding, L., DeNardo, D. G., Hawkins, W. G., Fields, R. C., et al. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011785 · Cited by 9
Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC
Musiu, C., Lupo, F., Agostini, A., Lionetto, G., Bevere, M., Paiella, S., Carbone, C., Corbo, V., Ugel, S., & Sanctis, F. D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1341079 · Cited by 10
The multi-faceted roles of cancer-associated fibroblasts in pancreatic cancer
Kwon, J. Y., Vera, R. E., & Fernández-Zapico, M. E. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111584 · Cited by 11
Fric, P., & Zavoral, M. (2012) · Pancreas · doi:10.1097/mpa.0b013e31823b5827 · Cited by 10
Shi, T., Yao, L., Han, Y., Hao, P., & Lu, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215400 · Cited by 11
Ye, C., Li, W., Yu, H.-H., Feng, Q.-P., Wu, X., Zhu, Y., Hu, M., Xiang, S.-Y., & Yu, S. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111370 · Cited by 11
Brown, K. M., Xue, A., Smith, R. C., Samra, J. S., Gill, A. J., & Hugh, T. J. (2021) · Cancer Medicine · doi:10.1002/cam4.4452 · Cited by 10
Chen, Q., Wang, X., Zheng, Y., Ye, T., Liu, J., Wang, J., Zhang, W., Wu, F., Bo, H., Shao, H., et al. (2023) · Cancer · doi:10.1002/cncr.34935 · Cited by 10
Reading the Tea Leaves of Tumor-Mediated Immunosuppression
Orentas, R. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3792 · Cited by 10
Parmiani, G., & Maccalli, C. (2012) · OncoImmunology · doi:10.4161/onci.21455 · Cited by 10
Mesenchymal Cell Plasticity and Perfidy in Epithelial Malignancy
Puré, E., & Hingorani, S. R. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.02.007 · Cited by 10
Yu, J., Piazza, A. N., Sparks, S., Hind, L. E., Niles, D. J., Ingram, P., Huang, W. C., Ricke, W. A., Jarrard, D. F., Huttenlocher, A., et al. (2021) · Integrative Biology · doi:10.1093/intbio/zyab004 · Cited by 10
Naito, Y. (2025) · Cancer Science · doi:10.1111/cas.70133 · Cited by 10
“A study using a mouse PDAC model that specifically eliminates FAP-positive cancer stromal cells from primary tumors showed that FAP-positive CAFs suppress antitumor immune effects via CXC-chemokine ligand 12 (CXCL12) production [44, 45].”
Tian, H., Zhao, S., Nie, F., Yin, Q., Wang, S., Liu, J., Ju, J., Yang, P., & Yang, C. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.07.027 · Cited by 9
Intratumoral Three-Cell-Type Clusters Are a Conserved Feature of Endogenous Antitumor Immunity
Damle, S., Carter, J. A., Goodsell, K. E., Pineda, J. M. B., Dickerson, L. K., Jiang, X., Mudd, J. L., Walsh, T., Kenerson, H. L., Cernak, J., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0062 · Cited by 9
Garate-Soraluze, E., Martínez-Zubiaurre, I., & Rodriguez-Ruiz, M. E. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009702 · Cited by 9
“31 Similarly, targeting CXCL12 derived from FAP-expressing CAFs sensitized otherwise unresponsive pancreatic tumors to combined α - cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and α - programmed death-ligand 1 (PD-L1) checkpoint blockade.”
Perez, K. J., Costa, A. D., Jordan, A., Karasic, T. B., Elganainy, D., Kim, S., Yuan, C., Gui, D. Y., Tan, R., Hong, S. C., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01165-8 · Cited by 10
Stromal inflammation, fibrosis and cancer: An old intuition with promising potential
Oey, O., Sunjaya, A. F., Khan, Y., & Redfern, A. D. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i7.230 · Cited by 10
Current status of FAP-directed cancer theranostics: a bibliometric analysis
Ruan, D., Wu, S., Lin, X., Zhao, L., Cai, J., Xu, W., Pang, Y., Xie, Q., Qu, X., & Chen, H. (2024) · Biophysics Reports · doi:10.52601/bpr.2024.240022 · Cited by 9
Dong, L., Li, Y., Song, X., Sun, C., & Song, X. (2024) · BMC Cancer · doi:10.1186/s12885-024-12907-1 · Cited by 9
Modiano, J. F., Lindborg, B. A., McElmurry, R. T., Lewellen, M., Forster, C. L., Zamora, E. A., Schaack, J. B., Bellgrau, D., O’Brien, T. D., & Tolar, J. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1749-6 · Cited by 9
“Experimental data show that IFNγ or tumor necrosis-α (TNFα)dependent licensing is necessary for these cells to alter the inflammatory environment, inhibit T cell activation, and promote tumor growth [49–53].”
Vallerand, D., Massonnet, G., Kebir, F., Gentien, D., Maciorowski, Z., de la Grange, P., Sigal‐Zafrani, B., Richardson, M., Humbert, S., Thuleau, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157670 · Cited by 9
Xue, D., Liang, Y., Duan, S., He, J., Su, J., Zhu, J., Hu, N., Liu, J., Zhao, Y., & Lü, X. (2016) · Oncology Reports · doi:10.3892/or.2016.5128 · Cited by 13
Differential induction of T-cell tolerance by tumour fibroblast subsets
Chua, Z. M. X., Tajebe, F., Abuwarwar, M. H., & Fletcher, A. L. (2024) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102410 · Cited by 9
Ströjby, S., Eberstål, S., Svensson, A., Fritzell, S., Bexell, D., Siesjö, P., Darabi, A., & Bengzon, J. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.07.014 · Cited by 9
Microenvironmental InterFereNce of metabolism regulates chemosensitivity
Akkari, L., & Joyce, J. A. (2016) · Cell Research · doi:10.1038/cr.2016.82 · Cited by 9
Wei, T., Song, J., Liang, K., Li, L., Mo, X., Huang, Z., Chen, G., Mao, N., & Yang, J. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03489-z · Cited by 12
Molecular insights into the development of T cell-based immunotherapy for prostate cancer
Dong, B., Minze, L. J., Xue, W., & Chen, W. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.962515 · Cited by 9
Cai, S., Zhao, M., Yang, G., Li, C., Hu, M., Yang, L., Xing, L., & Sun, X. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112434 · Cited by 8
Asadi, M., Zafari, V., Mohammadi, S. S., Shanehbandi, D., Mert, U., Soleimani, Z., Caner, A., & Zarredar, H. (2024) · Bioimpacts · doi:10.34172/bi.30713 · Cited by 11
Pereira, F. C., Zheng, Q., Hicks, J. L., Roy, S., Jones, T., Pomper, M. G., Antony, L., Meeker, A. K., Yegnasubramanian, S., Marzo, A. M. D., et al. (2025) · Pathology · doi:10.1016/j.pathol.2024.12.637 · Cited by 9
Relationship between PD-L1 expression and [18F]FAPI versus [18F]FDG uptake on PET/CT in lung cancer
Qin, J., Han, C., Li, H., Wang, Z., Hu, X., Liu, L., Zhu, S., Zhao, J., Sun, Y., & Wei, Y. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07201-6 · Cited by 8
Microphysiological Solid Tumor Models in Hydrogel Beads for CAR T Cell Immunotherapy Evaluation
Peng, X., Janićijević, Ž., Loureiro, L. R., Hoffmann, L., Lee, P. S., Çela, I., Kruppke, B., Kegler, A., Feldmann, A., Gorodetska, I., et al. (2025) · Advanced Science · doi:10.1002/advs.202508267 · Cited by 9
Xijing, L., & Cheng, B. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109240 · Cited by 8
Metadata
- Authors
- Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- Wellcome Trust Immunology Unit, Department of Medicine, University of Cambridge, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, UK.
- Cancer Research UK (GB)
- Corresponding author
- Kraman, Matthew
- Bambrough, Paul J.
- Arnold, James N.
- Fearon, Douglas T.
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 827-830
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2048253455
- Cited by
- 1,134
- References
- 30
- Citations by year
- 2026: 55 · 2025: 71 · 2024: 81 · 2023: 80 · 2022: 90 · 2021: 106 · 2020: 95 · 2019: 75 · 2018: 55 · 2017: 59 · 2016: 76 · 2015: 69 · 2014: 66 · 2013: 65 · 2012: 60
- FWCI
- 25.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- fibroblast activation protein, tumor stroma, tumor microenvironment, antitumor immunity, immunosuppression, Lewis lung carcinoma, pancreatic ductal adenocarcinoma, interferon-gamma, TNF-α, transgenic mouse model
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Antigens, Neoplasm, Cell Survival, Immune Tolerance, Interferon-gamma, Membrane Proteins, Mice, Transgenic, Necrosis, Neoplasm Transplantation, Endopeptidases, Serine Endopeptidases, Tumor Necrosis Factor-alpha, Cell Hypoxia, Stromal Cells, Gelatinases, Carcinoma, Lewis Lung, Cancer Vaccines, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.